Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trialsKayvon Modjarrad, Nelson L. Michael, Janice Tennant et al.|The Lancet|2017Cited by 196
Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donorVincent Dussupt, Nelson L. Michael, Rajeshwer S. Sankhala et al.|Nature Medicine|2020Cited by 88
Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trialKirsten E. Lyke, Robert Edelman, Joel V. Chua et al.|The Lancet Infectious Diseases|2024Cited by 24
Pre-existing Immunity to Japanese Encephalitis Virus Alters CD4 T Cell Responses to Zika Virus Inactivated VaccineNoemia S. Lima, Lydie Trautmann, Damee Moon et al.|Frontiers in Immunology|2021Cited by 19